Collaborations

Santen, Oakwood Laboratories sign deal for development of diabetic macular edema technology

Published in Drug Week, April 28th, 2006

Santen Pharmaceutical Co., Ltd., of Osaka, has signed a development and license agreement with Oakwood Laboratories LLC, concerning the development and license of a steroid microsphere-based product for diabetic macular edema treatment (development code named DE-102).

Under the agreement, taking advantage of Oakwood's microsphere-based technology platform (Chroniject), they will develop processing technology and a sustained release system for DE-102.

Diabetic macular edema is an ophthalmic disorder associated with swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula, which is in the central portion...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-04-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry